title: Determinants of blood uric acid levels in a dyslipidemic Arab population.
abstract: OBJECTIVE
  The objective of this study was to explore the relationships between circulating uric acid and lipid levels and components of the metabolic syndrome (MetS) in Arab dyslipidemic patients, a group already at high coronary artery disease risk.
  
  
  METHODS
  The medical records of 1,229 subjects (632 men, 597 women) referred for treatment of dyslipidemia and followed up for at least 12 months were reviewed. Serum levels of uric acid and lipids (total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein) and other variables in the National Cholesterol Education Program ATP III criteria definition of MetS were assessed at initial presentation and every 4- 6 months, under specific lipid-lowering treatment (statins and/or fibrates), in each of the subjects. Their respective associations were explored by appropriate logistic regression techniques with control for confounding risk factors, including age, gender and body mass index.
  
  
  RESULTS
  306 subjects (24.9%) of the study population were hyperuricemic; they were more likely to be men, obese and diabetic. Also the serum uric acid level (mean ± SD) was greater in men with MetS compared with men without (377.0 ± 98.0 vs. 361.6 ± 83.1 μmol/l, p < 0.05), an observation not reproduced in women. Uric acid levels had significant associations with the presence of fasting hyperglycemia, hypertension and large waist circumference (WC) in men, but only with large WC in women. With statin treatment, uric acid levels decreased by 10% within 1 year of treatment; with fibrates, uric acid levels remained unchanged or slightly increased.
  
  
  CONCLUSIONS
  The data showed that hyperuricemia is common in dyslipidemic patients in Kuwait, where its important determinants are male sex, obesity, diabetes and statin treatment.
authors.affiliation: Kuwait University Faculty of Medicine, Jabriya, Kuwait.
authors.forename: Ahoud F
authors.initials: AF
authors.lastname: Al-Meshaweh
authors.forename: Yaqoub
authors.initials: Y
authors.lastname: Jafar
authors.forename: Mohammad
authors.initials: M
authors.lastname: Asem
authors.forename: Abayomi O
authors.initials: AO
authors.lastname: Akanji
mesh_terms: D000328:Adult; D018912:Arabs / Q000208:ethnology*; D015992:Body Mass Index; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000097:blood; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000097:blood* / Q000453:epidemiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D033461:Hyperuricemia / Q000097:blood*; D007333:Insulin Resistance; D007730:Kuwait / Q000453:epidemiology; D008055:Lipids / Q000097:blood; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D014527:Uric Acid